A prospective, open label, randomized, controlled trial of tocilizumab versus cyclophosphamide in patients with microscopic polyangiitis

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2013
INTERVENTION: Tocilizumab group Cyclophosphamide group CONDITION: Microscopic polyangiitis PRIMARY OUTCOME: Improvement of major clinical signs and symptoms at week 24. (MPO‐ANCA or PR3‐ANCA, serum CRP and ESR, BVAS2003, VDI) INCLUSION CRITERIA: Patients who fulfilled the 2007 Watts algorithm. 1) Watts R et al. Development and validation of a consensus methodology for the classification of theANCA‐associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007 Feb; 66(2): 222‐7.
Epistemonikos ID: 787e132bed25922638744f17494fed74881d8f6d
First added on: Aug 22, 2024